Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nemus Bioscience (NMUS)

Nemus Bioscience (NMUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Glaucoma Drugs Market Opportunities, Demands and Growth Revenue by 2025 | Brandessence Market Research Report

AERI : 12.71 (+2.67%)
AGN : 193.02 (+0.02%)
CANF : 2.33 (+6.39%)
ITEK : 3.04 (-5.00%)
MRK : 83.48 (-0.07%)
NMUS : 0.6500 (-9.52%)
NVS : 84.65 (-0.84%)
OCAT : 8.47 (+0.12%)
OCUL : 7.99 (-0.93%)
OHRP : 5.39 (+30.19%)
PRGO : 53.40 (+1.46%)
PFE : 38.06 (-0.29%)
SNPHF : 17.5000 (+2.04%)
SCMP : 18.05 (+0.28%)
TEVA : 11.50 (-0.61%)
VRX.TO : 30.80 (-3.33%)
Europe Glaucoma Drugs Market Share, Size, Future Demand, Application, Top Leading Player, Upcoming Trends, Region By Forecast To 2025

A research report on features a succinct analysis on the latest market trends. The report also includes detailed abstracts about statistics, revenue forecasts and market valuation, which additionally...

AERI : 12.71 (+2.67%)
AGN : 193.02 (+0.02%)
CANF : 2.33 (+6.39%)
ITEK : 3.04 (-5.00%)
MRK : 83.48 (-0.07%)
NMUS : 0.6500 (-9.52%)
NVS : 84.65 (-0.84%)
OCAT : 8.47 (+0.12%)
OCUL : 7.99 (-0.93%)
OHRP : 5.39 (+30.19%)
PRGO : 53.40 (+1.46%)
PFE : 38.06 (-0.29%)
SNPHF : 17.5000 (+2.04%)
SCMP : 18.05 (+0.28%)
TEVA : 11.50 (-0.61%)
VRX.TO : 30.80 (-3.33%)
Glaucoma Drugs Market 2019 Top Key Players are Aerie Pharmaceuticals, Allergan plc, Bausch & Lomb Incorporated, Inotek Pharmaceuticals, Merck & Co. Inc., Pfizer Inc., Merck & Co., and Forecast to 2025

: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?.Rise in prevalence of eye disorders such as Presbyopia, Macular Degeneration and Diabetic Retinopathy in the aging population...

AERI : 12.71 (+2.67%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 83.48 (-0.07%)
NMUS : 0.6500 (-9.52%)
NVS : 84.65 (-0.84%)
OCAT : 8.47 (+0.12%)
OCUL : 7.99 (-0.93%)
OHRP : 5.39 (+30.19%)
PRGO : 53.40 (+1.46%)
PFE : 38.06 (-0.29%)
SNPHF : 17.5000 (+2.04%)
SCMP : 18.05 (+0.28%)
TEVA : 11.50 (-0.61%)
VRX.TO : 30.80 (-3.33%)
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments

NMUS : 0.6500 (-9.52%)
EMBI : 0.0500 (unch)
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing

Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study

NMUS : 0.6500 (-9.52%)
Imaging3 Update on Execution of Letter of Intent for Reverse Acquisition by Grapefruit Boulevard Investments, Inc.

Imaging3, Inc. (OTCQB:IGNG, "Imaging3" or the "Company"), a development stage company introducing disruptive technologies in the medical imaging industry, is updating and clarifying last week's announcement...

IGNG : 0.0670 (+3.08%)
LVCA : 0.0110 (+15.79%)
NMUS : 0.6500 (-9.52%)
OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations...

ACRGF : 3.1300 (-1.57%)
ALEAF : 0.4279 (-0.49%)
ARREF : 0.3871 (-3.22%)
CWBHF : 3.7300 (+6.88%)
CORVF : 2.7550 (-4.82%)
CRLBF : 7.2500 (+1.05%)
DYAI : 7.66 (-13.84%)
ELLXF : 0.1250 (-3.40%)
EMHTF : 0.1377 (+7.16%)
GLDLF : 1.7900 (-0.99%)
GTBIF : 16.0100 (+3.62%)
GRWG : 13.24 (+5.92%)
HEOFF : 0.8000 (-6.48%)
ITHUF : 0.0610 (+1.67%)
IMLFF : 5.3144 (+3.01%)
ISYRF : 1.3448 (+1.11%)
MMNFF : 0.1724 (-5.74%)
MTAFF : 1.2500 (-4.58%)
MJARF : 0.0541 (+27.29%)
NUPMF : 4.6600 (+0.22%)
NLST : 0.5575 (+5.87%)
STLHF : 1.0100 (-1.42%)
TRLFF : 0.0296 (-2.95%)
AITB : 4.6500 (-6.44%)
ALYE : 0.5749 (+85.45%)
ARTH : 0.1950 (-2.01%)
ARHH : 0.9100 (unch)
ATEA : 11.9500 (unch)
BICXD : 4.5400 (-9.02%)
BRTI : 0.0038 (-2.56%)
CNBX : 0.1940 (-5.37%)
CLOK : 0.4400 (-2.22%)
CVSI : 0.7100 (+8.23%)
DUOT : 4.15 (+1.45%)
EVLLF : 0.4953 (+2.12%)
FLUX : 4.20 (-46.84%)
GBPT : 0.2000 (-23.08%)
GTBP : 0.1780 (-0.06%)
KSHB : 0.6518 (-1.24%)
MRMD : 0.1953 (-4.55%)
MLCPF : 2.5671 (unch)
MRIC : 5.14 (-0.48%)
NMUS : 0.6500 (-9.52%)
NWGI : 1.9800 (-1.00%)
OWCP : 0.0088 (+3.53%)
PPCB : 0.0017 (+21.43%)
QBIO : 1.6000 (-3.03%)
RSSS : 2.79 (+5.68%)
VTLR : 0.0301 (-35.96%)
WIZD : 0.8000 (-20.00%)
OTCM : 32.0000 (+1.59%)
Nemus Bioscience to Present at 31st Annual ROTH Conference

via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that...

NMUS : 0.6500 (-9.52%)
Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues

Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation

NMUS : 0.6500 (-9.52%)
Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog

Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina

NMUS : 0.6500 (-9.52%)
Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma

via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that...

NMUS : 0.6500 (-9.52%)
Nemus Bioscience to Present at BIO CEO & Investor Conference

via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that...

NMUS : 0.6500 (-9.52%)
Innovative Developments in Biotechnology set to Spur the Market Growth

NEW YORK, January 23, 2019 /PRNewswire/ --

SNET : 0.0103 (+63.49%)
NMUS : 0.6500 (-9.52%)
ATBPF : 0.3140 (-1.47%)
PMCB : 0.0140 (unch)
ENDV : 0.1075 (-9.21%)
Nemus Bioscience to Present at the NobleCon XV and 8th Annual Glaucoma 360 New Horizons Forum

via NEWMEDIAWIRE - Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that...

NMUS : 0.6500 (-9.52%)

Van Meerten Stock Picks

The 5 Best MidCaps
I wanted to find the 5 Mid Caps that have had the best momentum over the past year so I used Barchart to sort the S&P 400 MidCap Stock Index for the stocks with the highest Weighted Alpha and technical buying signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar